KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Receivables (2016 - 2025)

Resmed (RMD) has disclosed Receivables for 16 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 15.45% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2025, up 15.45%, and an annual FY2025 reading of $990.7 million, up 13.16% over the prior year.
  • Receivables was $1.0 billion for Q4 2025 at Resmed, up from $958.4 million in the prior quarter.
  • Across five years, Receivables topped out at $1.0 billion in Q4 2025 and bottomed at $534.2 million in Q1 2022.
  • Average Receivables over 5 years is $756.9 million, with a median of $731.0 million recorded in 2023.
  • The sharpest move saw Receivables decreased 4.59% in 2021, then soared 33.31% in 2023.
  • Year by year, Receivables stood at $550.7 million in 2021, then grew by 26.27% to $695.4 million in 2022, then rose by 9.91% to $764.3 million in 2023, then grew by 18.66% to $907.0 million in 2024, then rose by 15.45% to $1.0 billion in 2025.
  • Business Quant data shows Receivables for RMD at $1.0 billion in Q4 2025, $958.4 million in Q3 2025, and $990.7 million in Q2 2025.